Apple has moved its long-running non-invasive blood sugar monitoring project under new leadership, shifting oversight from platform architecture chief Tim Millet to senior engineer Zongjian Chen. This change comes after more than 15 years of development on technology that could transform diabetes management for millions of users.

The proposed system uses lasers to emit specific light wavelengths into skin tissue, targeting interstitial fluid where glucose concentrations can be measured. Light reflection patterns help determine glucose levels, with algorithms processing the data. Beyond tracking, the feature could identify prediabetes warning signs, offering preventive health benefits.

Despite the leadership transition, the technology remains years away from consumer availability. Apple has struggled with accuracy and miniaturization challenges typical of medical-grade sensors. The company faces competition from dedicated CGM makers like Dexcom and Abbott.

If Apple successfully ships this capability, it would eliminate the need for finger-prick tests and separate monitoring devices. That breakthrough could establish the Apple Watch as essential health hardware rather than just a fitness accessory.